Casodex 150-mg Compassionate Use Trial for Subjects with Prostate Cancer
Study identifier:7054US/0014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Other
Official Title
A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer
Medical condition
Adenocarcinoma of the prostate
Phase
-
Healthy volunteers
None
Study drug
Bicalutamide (Casodex)
Sex
Male
Actual Enrollment
-
Study type
Expanded Access
Age
18 Years +
Date
Study Start Date: -
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
